Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. New Morningstar Analyst Report for Johnson & Johnson

      Stock Reports

      Wed, 16 Apr 2014

      advancement through many management positions in the drug and device divisions at J&J along with a managerial post at Novartis gives him the broad experience set needed to run the massive health conglomerate. The first major test of Gorsky's

    2. Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race

      Headlines

      Mon, 14 Apr 2014

      By Peter Geschek : Palbociclib update Early approval hopes of palbociclib, based on Phase 2 data, are fading. At the annual meeting of the American Association for Cancer Research in San Diego, Pfizer ( PFE ) presented details of the Phase 2 study . The drug cut in half the risk that cancer would

    3. New Morningstar Analyst Report for Biogen Idec Inc

      Stock Reports

      Fri, 11 Apr 2014

      is losing its edge as the leading MS drug, as similar competitors nip at its heels and novel oral therapies, such as Novartis ' Gilenya and Sanofi's Aubagio, enter the market.Tysabri's efficacy could be overshadowed by worrisome side effects

    4. New Morningstar Analyst Report for Roche Holding AG

      Stock Reports

      Fri, 11 Apr 2014

      pooled voting rights--including board members Andre Hoffmann and Andreas Oeri--owns 45% of voting shares, and Novartis owns 33% of voting shares. Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical

    5. UPDATE 2-French antitrust watchdog probes Roche and Novartis over eye drug

      Headlines

      Thu, 10 Apr 2014

      * French regulator probes Swiss firms over wet AMD treatments

    6. UPDATE 1-French antitrust watchdog probes Roche and Novartis over eye drug

      Headlines

      Thu, 10 Apr 2014

      * French regulator probes Swiss firms over wet AMD treatments

    7. Roche says did not collude with Novartis to restrict competition

      Headlines

      Thu, 10 Apr 2014

      ZURICH, April 10 (Reuters) - Swiss drugmaker Roche said on Thursday that it had not colluded with Novartis to restrict competition for eye disease treatments.

    8. French antitrust body probes Roche, Novartis over eye treatment

      Headlines

      Thu, 10 Apr 2014

      PARIS/ZURICH, April 10 (Reuters) - France's competition authority is investigating drugmakers Roche and Novartis on suspicion they were involved in anti-competitive practices in respect of eye...

    9. Leadership changes at Novartis

      Headlines

      Wed, 9 Apr 2014

      CEO Joe Jimenez taps Jeff George to run Alcon and Richard Francis to run Sandoz. Mr. George has been with Novartis ( NVS +0.4% ) since 2007 in various executive roles including the last five years managing Sandoz. He takes the helm

    10. Novartis names new heads for Alcon and Sandoz divisions

      Headlines

      Wed, 9 Apr 2014

      ZURICH, April 9 (Reuters) - Swiss drugmaker Novartis has appointed new heads of its eyecare business Alcon and generics division Sandoz, the group's second and third largest businesses after pharmaceuticals.

    « Prev12345Next »
    Content Partners